David Pierce Biography and Net Worth

EVP of Boston Scientific

David A. Pierce is our executive vice president and president, MedSurg a position he has held since April 2018, and president, Endoscopy, a role he has held since February 2020. In this role, he has direct responsibility for the Endoscopy business, corporate marketing and market access, and corporate sales operations, as well as oversight responsibility for the Urology and Pelvic Health business. Prior to his current role, Mr. Pierce served as the Senior Vice President and President, Urology and Pelvic Health since July 2016. In that role, he developed and executed strategies to bring to market industry-leading solutions for treating patients with urological, urogynecological and gynecological diseases. Previously, Mr. Pierce served as senior vice president and president, Endoscopy since 2011, and vice president, marketing for Endoscopy as well as group marketing director in the Endoscopy business. He joined Boston Scientific in 1991 as a territory manager before assuming management-level positions of increasing responsibility. Mr. Pierce is a member of our Global Council for Inclusion and is the executive sponsor of our VETS employee resource group, which is focused on cultivating gratitude and service to others, particularly active duty veterans and their families. Prior to joining Boston Scientific, Mr. Pierce also served as senior sales representative for Airborne Express and as a Captain in the United States Army. He earned a B.S. in Business Administration from Norwich University and an M.B.A. from Boston University.

What is David A. Pierce's net worth?: The estimated net worth of David A. Pierce is at least $204,245.70 as of June 3rd, 2021. Mr. Pierce owns 2,057 shares of Boston Scientific stock worth more than $204,246 as of March 30th. This net worth approximation does not reflect any other investments that Mr. Pierce may own. Learn More about David A. Pierce's net worth.
How do I contact David A. Pierce?: The corporate mailing address for Mr. Pierce and other Boston Scientific executives is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. Boston Scientific can also be reached via phone at (508) 683-4000 and via email at bsxinvestorrelations@bsci.com. Learn More on David A. Pierce's contact information.
Has David A. Pierce been buying or selling shares of Boston Scientific?: David A. Pierce has not been actively trading shares of Boston Scientific within the last three months. Most recently, David A. Pierce sold 1,884 shares of the business's stock in a transaction on Tuesday, February 22nd. The shares were sold at an average price of $42.55, for a transaction totalling $80,164.20. Learn More on David A. Pierce's trading history.
Who are Boston Scientific's active insiders?: Boston Scientific's insider roster includes Kevin Ballinger (EVP), Supratim Bose (EVP), Daniel Brennan (CFO), Vance Brown (SVP), Arthur Butcher (EVP), Wendy Carruthers (SVP), Nelda Connors (Director), Keith Dawkins (EVP), Charles Dockendorff (Director), Jodi Eddy (SVP), Joseph Fitzgerald (EVP), Edward Ludwig (Director), Edward Ludwig (Director), Edward Mackey (EVP), Michael Mahoney (CEO), Ian Meredith (EVP), Jeffrey Mirviss (EVP), Jonathan Monson (CAO), Maulik Nanavaty (SVP), Scott Olson (SVP), Michael Phalen (EVP), David Pierce (EVP), Timothy Pratt (EVP), Desiree Ralls-Morrison (SVP), Meghan Scanlon (SVP), John Sorenson (SVP), Eric Thepaut (EVP), Xin Wang (SVP), and David Wichmann (Director). Learn More on Boston Scientific's active insiders.
Are insiders buying or selling shares of Boston Scientific?: During the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 568,055 shares worth more than $49,843,973.61. The most recent insider tranaction occured on February, 24th when EVP Jeffrey B Mirviss sold 4,675 shares worth more than $487,368.75. Insiders at Boston Scientific own 0.5% of the company. Learn More about insider trades at Boston Scientific.
Information on this page was last updated on 2/24/2025.

David A. Pierce Insider Trading History at Boston Scientific

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/22/2022	Sell	1,884	$42.55	$80,164.20
2/18/2022	Sell	2,354	$42.88	$100,939.52
2/16/2022	Sell	1,956	$43.81	$85,692.36
12/20/2021	Sell	49,988	$39.90	$1,994,521.20
6/3/2021	Sell	1,654	$41.36	$68,409.44	2,057
3/16/2021	Sell	7,603	$39.36	$299,254.08	2,057
2/19/2021	Sell	1,484	$38.00	$56,392.00	9,660
2/4/2021	Sell	11,317	$38.00	$430,046.00
8/3/2020	Sell	2,385	$38.69	$92,275.65	7,016
7/22/2020	Sell	2,170	$38.00	$82,460.00	9,401
4/17/2020	Sell	14,793	$38.00	$562,134.00	15,597
2/25/2020	Sell	4,122	$41.15	$169,620.30	32,540
2/19/2020	Sell	1,511	$42.31	$63,930.41	32,540
1/2/2020	Sell	2,152	$45.50	$97,916.00	36,127
12/2/2019	Sell	5,000	$43.33	$216,650.00	29,201
11/1/2019	Sell	5,000	$42.05	$210,250.00	29,201
10/1/2019	Sell	5,000	$41.14	$205,700.00	29,201
9/3/2019	Sell	5,000	$42.50	$212,500.00	29,201
8/2/2019	Sell	5,000	$42.62	$213,100.00	29,201
6/3/2019	Sell	5,140	$38.45	$197,633.00	27,173
5/1/2019	Sell	5,000	$37.10	$185,500.00
4/1/2019	Sell	5,000	$38.82	$194,100.00	29,201
3/18/2019	Sell	14,739	$39.13	$576,737.07	38,601
3/6/2019	Sell	1,357	$40.25	$54,619.25	38,940
2/26/2019	Sell	4,508	$39.83	$179,553.64	38,940
2/20/2019	Sell	1,952	$39.86	$77,806.72	52,223
2/1/2019	Sell	5,000	$38.15	$190,750.00	29,201
1/8/2019	Sell	5,000	$35.00	$175,000.00	39,520
12/3/2018	Sell	5,000	$38.11	$190,550.00
11/1/2018	Sell	5,000	$36.40	$182,000.00
10/1/2018	Sell	5,000	$38.80	$194,000.00
9/4/2018	Sell	5,000	$36.02	$180,100.00
8/1/2018	Sell	5,000	$33.66	$168,300.00	29,201
7/2/2018	Sell	5,000	$32.42	$162,100.00	29,201
6/7/2018	Sell	1,650	$30.83	$50,869.50
6/1/2018	Sell	5,000	$30.58	$152,900.00	29,201
5/1/2018	Sell	5,000	$28.80	$144,000.00	29,201
4/2/2018	Sell	5,000	$27.22	$136,100.00
2/28/2018	Sell	4,508	$27.54	$124,150.32
2/21/2018	Sell	16,286	$27.00	$439,722.00
2/1/2018	Sell	5,152	$27.43	$141,319.36	29,353
1/11/2018	Sell	8,763	$27.74	$243,085.62	24,201
1/9/2018	Sell	5,152	$27.00	$139,104.00	38,116
6/9/2017	Sell	13,562	$28.00	$379,736.00	33,701
6/2/2017	Sell	2,972	$27.70	$82,324.40	28,572
4/26/2017	Sell	10,250	$26.00	$266,500.00	35,850
3/3/2017	Sell	25,012	$25.01	$625,550.12	25,600
2/27/2017	Sell	3,417	$24.84	$84,878.28	34,267
1/9/2017	Sell	10,232	$22.24	$227,559.68	25,600
7/20/2016	Sell	2,480	$24.03	$59,594.40	28,080
3/20/2015	Sell	18,050	$18.00	$324,900.00
3/9/2015	Sell	2,561	$16.54	$42,358.94
3/3/2015	Sell	8,983	$16.79	$150,824.57
2/27/2015	Sell	19,046	$16.80	$319,972.80
2/19/2015	Sell	11,958	$16.46	$196,828.68
2/9/2015	Sell	5,000	$14.66	$73,300.00
1/8/2015	Sell	18,612	$14.31	$266,337.72
12/8/2014	Sell	5,000	$12.90	$64,500.00
7/30/2014	Sell	157	$12.97	$2,036.29

See Full Table

David A. Pierce Buying and Selling Activity at Boston Scientific

Boston Scientific Company Overview

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Today's Range

Now: $99.29

$98.02

$100.42

50 Day Range

MA: $102.16

$93.79

$106.20

2 Week Range

Now: $99.29

$66.80

$107.17

Volume

7,402,670 shs

Average Volume

6,051,507 shs

Market Capitalization

$146.86 billion

P/E Ratio

79.43

Dividend Yield

N/A

Beta

0.77